Cargando…

Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer

Resistance to androgen-receptor (AR) directed therapies is, among other factors, associated with Myc transcription factors that are involved in development and progression of many cancers. Overexpression of N-Myc protein in prostate cancer (PCa) leads to its transformation to advanced neuroendocrine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ton, Anh-Tien, Singh, Kriti, Morin, Hélène, Ban, Fuqiang, Leblanc, Eric, Lee, Joseph, Lallous, Nada, Cherkasov, Artem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663809/ https://www.ncbi.nlm.nih.gov/pubmed/33167327 http://dx.doi.org/10.3390/ijms21218277

Ejemplares similares

Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer
por: Ton, Anh-Tien, et al.
Publicado: (2022)

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
por: Radaeva, Mariia, et al.
Publicado: (2022)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
por: Ban, Fuqiang, et al.
Publicado: (2021)

Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor
por: Radaeva, Mariia, et al.
Publicado: (2021)

Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer
por: Carabet, Lavinia A., et al.
Publicado: (2019)

Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies
por: Snow, Oliver, et al.
Publicado: (2020)

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
por: Lallous, Nada, et al.
Publicado: (2013)

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α
por: Singh, Kriti, et al.
Publicado: (2015)

Neurokinin-1 receptor drives PKCɑ-AURKA/N-Myc signaling to facilitate the neuroendocrine progression of prostate cancer
por: Zhang, Xiao-Wei, et al.
Publicado: (2023)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
por: Lallous, Nada, et al.
Publicado: (2021)

Targeting SARS-CoV-2 papain-like protease in the postvaccine era
por: Ton, Anh-Tien, et al.
Publicado: (2022)

Computer-Aided Ligand Discovery for Estrogen Receptor Alpha
por: Bafna, Divya, et al.
Publicado: (2020)

Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery
por: Gentile, Francesco, et al.
Publicado: (2020)

PurificationDB: database of purification conditions for proteins
por: Garland, Olivia, et al.
Publicado: (2023)

Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus Deep Docking of 40 billion small molecules
por: Gentile, Francesco, et al.
Publicado: (2021)

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers
por: Singh, Kriti, et al.
Publicado: (2018)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Discovery of Novel Lin28 Inhibitors to Suppress Cancer Cell Stemness
por: Radaeva, Mariia, et al.
Publicado: (2022)

Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells
por: Yang, Yan, et al.
Publicado: (2020)

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
por: Lallous, Nada, et al.
Publicado: (2016)

Computer-Aided Discovery of Small Molecule Inhibitors of Transcriptional Activity of TLX (NR2E1) Nuclear Receptor
por: Dueva, Evgenia, et al.
Publicado: (2018)

OTHR-02. CHIMERIC AURORA A KINASE (AURKA) DEGRADERS EFFICIENTLY TARGET N-MYC
por: Valinciute, Gintvile, et al.
Publicado: (2023)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors
por: Ben-Eltriki, Mohamed, et al.
Publicado: (2018)

Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site
por: Lee, Jaeyong, et al.
Publicado: (2020)

Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches
por: Carabet, Lavinia A., et al.
Publicado: (2018)

AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)

Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer
por: Ekpenyong, Oscar, et al.
Publicado: (2020)

SimBoost: a read-across approach for predicting drug–target binding affinities using gradient boosting machines
por: He, Tong, et al.
Publicado: (2017)

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma()
por: Felgenhauer, Joshua, et al.
Publicado: (2018)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2014)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2015)

Integrated pan‐cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance
por: Miralaei, Noushin, et al.
Publicado: (2021)

CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
por: Chen, Xi, et al.
Publicado: (2022)

Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells
por: Pathria, G, et al.
Publicado: (2016)

AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses
por: Meng, Bi, et al.
Publicado: (2023)

Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models
por: Sooreshjani, Moloud Aflaki, et al.
Publicado: (2021)

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
por: Donnella, Hayley J, et al.
Publicado: (2018)

MicroRNA expression profiles in extracellular vesicles and intracellular of AURKA inhibitor-induced senescent neuroblastoma cells
por: Zhou, Xuefeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_84kvr5kirtd4cudicuf06j8s9f